Cullinan Therapeutics Receives FDA Orphan Drug Designation for Novel FLT3xCD3 T Cell Engager CLN-049 in Relapsed/Refractory AML
核心洞察
The FDA has granted Orphan Drug Designation to CLN-049, a novel FLT3xCD3 T cell engager developed by Cullinan Therapeutics for treating relapsed/refractory acute myeloid leukemia.
CLN-049 targets both mutated and non-mutated FLT3 (搜索)-expressing leukemia cells, making it applicable to a broad population of AML patients regardless of FLT3 mutational status.
The designation provides development incentives including tax credits, FDA user fee exemptions, and potential seven years of market exclusivity following approval.
Cullinan Therapeutics announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to CLN-049, a novel investigational FLT3xCD3 T cell engager, for the treatment of relapsed/refractory acute myeloid leukemia. The designation underscores the significant unmet medical need in AML and the therapeutic potential of this immunotherapeutic approach.
"FDA Orphan Drug Designation for CLN-049 emphasizes both the urgent need for new therapies for people living with relapsed or refractory acute myeloid leukemia – including patients with TP53 (搜索)-mutated AML who currently face a particularly poor prognosis – and the potential of this FLT3 (搜索)-directed T cell engager to expand treatment options across the broadest population of AML patients," said Jeffrey Jones, MD, MBA, Chief Medical Officer at Cullinan Therapeutics.
Novel Mechanism Targets Broad AML Population
CLN-049 represents a new immunotherapeutic approach designed to target FLT3 (搜索)-expressing leukemia cells in both AML and myelodysplastic syndrome. The investigational therapy binds to both mutated and non-mutated FLT3, enabling targeted action regardless of FLT3 mutational status. This broad applicability makes the treatment potentially accessible to a wide population of AML patients.
The drug candidate has already received Fast Track designation from the FDA for the treatment of relapsed/refractory AML, indicating the agency's recognition of the urgent need for new therapeutic options in this patient population.
Clinical Development Program Underway
CLN-049 is currently being evaluated in two Phase 1 studies. The first is an open-label, multicenter, first-in-human, multiple ascending dose study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of intravenously administered CLN-049 in patients with relapsed/refractory AML or MDS. A parallel Phase 1 study is examining the treatment in patients with AML with measurable residual disease.
Jones noted that the orphan designation, "coupled with promising results from our ongoing Phase 1 program, reinforces a shared goal to rapidly advance novel therapies for patients living with AML."
Addressing Critical Unmet Need in AML
Acute myeloid leukemia affects approximately 22,000 people annually in the United States, with about half as many lives lost to the disease each year. Globally, AML affects an estimated 144,000 people annually, with approximately 130,000 deaths. The disease is characterized by the rapid growth of abnormal white blood cells that crowd out healthy cells, leading to infections, fatigue, and bleeding.
Despite recent advances, outcomes for patients with AML remain poor, particularly for those with relapsed or refractory disease, where five-year survival is 10% or less. Patients with high-risk genetic features, such as complex karyotype or TP53 (搜索) mutations, face especially limited options. Intensive treatments like chemotherapy and stem cell transplantation may be inaccessible for many older patients due to severe side effects.
Currently, there are no approved immunotherapies for AML, underscoring the urgent need for novel therapeutic approaches that can improve outcomes for patients facing this life-threatening disease.
Regulatory Benefits and Development Incentives
The FDA's Orphan Drug Designation provides orphan status to drugs intended to treat rare diseases affecting fewer than 200,000 people in the United States. The designation qualifies sponsors for several development incentives, including tax credits for qualified clinical trials, exemption from certain FDA user fees, and the potential for seven years of market exclusivity in the United States following marketing approval.
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing potential first- or best-in-class therapies for autoimmune diseases and cancer, with core expertise in T cell engagers that are established in oncology and advancing into autoimmune diseases.